OptimizeRx Reports Q3 Earnings Beat but Lowers 2026 Revenue Guidance
OptimizeRx (NASDAQ: OPRX) reported third-quarter financial results that exceeded analyst expectations on both the top and bottom lines. The company posted a Non-GAAP EPS of $0.20, beating estimates by $0.04, and revenue of $21.6 million, which surpassed consensus by $0.41 million despite representing a 17.2% year-over-year decline. Despite the quarterly beat, the company issued updated fiscal year 2026 guidance that fell short of market expectations. OptimizeRx now projects revenue between $87 million and $93 million, trailing the consensus estimate of $96.23 million. Following the announcement, shares experienced a significant decline in after-hours trading.
Tickers: $OPRX
Topics: earnings beat financial outlook guidance revision revenue miss